Global Antidepressant Market: Industry Analysis and Forecast (2020-2026) By Product, Depressive Disorder and Region

Global Antidepressant Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 2.7% during forecast period.

Global Antidepressant Market Overview:

Antidepressants are prescription drugs that are used to treat major depressive illness, anxiety disorders, chronic pain, and addictions. Dry mouth, weight gain, dizziness, migraines, sexual dysfunction and emotional blunting are all common antidepressant side effects.

Global Antidepressant Market Dynamics:

Rising cases of depression is one of the major factors driving the market growth.

Globally, increased cases of mental health issues are a major driver of the antidepressant drug industry's growth, as many customers rely on these prescriptions to treat depression, anxiety, and other mental illnesses. According to the World Health Organization, around 264 million individuals of all ages will be depressed by 2020. As a result, increased incidences of mental health illnesses are likely to propel the antidepressant industry forward. The rise in the senior population, the rise in the prevalence of depression, and the development of novel strategies for developing medications with fewer side effects are all driving the industry forward. Furthermore, rising public awareness of the disease and an increase in the number of people suffering from stress could propel the antidepressant drug industry forward. Ketamine, an anesthetic that has made waves for its surprising antidepressant effect, was approved by the Food and Drug Administration (FDA) in 2018. Because esketamine medication may be beneficial to individuals with treatment-resistant depression (those who have not responded to traditional therapies), the FDA has accelerated the approval procedure to make it more readily available. However, the market is projected to be hampered by the drug's poor efficacy and safety profiles, preference for non-pharmacological therapy, and a rise in the number of antidepressant patent expirations, resulting in a weak pipeline. Lexapro (escitalopram) and Celexa (citalopram) are antidepressants that are both used to treat depression. Lexapro also helps with anxiety. Nausea, insomnia, sweating, dry mouth, and sleepiness are some of the side effects that Lexapro and Celexa might induce. In 2018, the drugs' labels included a black box warning about an increased risk of suicide. As a result, the antidepressant market's growth is projected to be constrained by side effects and patent expiration. The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Antidepressant Market Segment Analysis:

The Global Antidepressant Market is segmented on the basis of Product and Depressive Disorder.

Based on Product, the Selective Serotonin Reuptake Inhibitor (SSRI) segment is expected to hold a dominant market share throughout the forecast period due to the significant quantity of these medications present. The most widely used antidepressants are selective serotonin reuptake inhibitors (SSRIs). They're quite effective and have fewer negative effects than other antidepressants. SSRIs work by preventing serotonin from being reabsorbed or reuptaken in the brain, which helps to reduce depression symptoms. Global Antidepressant Market To know about the Research Methodology :- Request Free Sample Report Based on Depressive Disorder, the Major Depressive Disorder segment is expected to account for dominant market share during the forecast period. The biological, psychological, and social sources of sadness are all possible causes of severe depressive disorder. Family history, substantial life changes, particular medications, chronic health conditions, and substance abuse are all key risk factors. According to the National Institute of Mental Health, 17.3 million adults in the United States experienced at least one major depressive episode in 2017. This figure represents 7.1% of all adults in the United States, and it is more common in women than in males. The average 12-month prevalence was 5.2%, with a lifetime prevalence of 11.32 %. As a result, over the projection period, the high frequency of major depressive illness is expected to drive up the demand for antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are most widely used to treat serious depression, however, there are certain therapies that can help to normalise depression-related brain abnormalities. As a result of the growing patient pool and new product introductions, the market is likely to rise rapidly throughout the forecast period.

Global Antidepressant Market Regional Insights:

Global Antidepressant Market 1

North America is the dominant region in the global market.

One of the primary drivers projected to fuel the overall growth of the antidepressant market in North America, notably in the United States, throughout the forecast period is the rising prevalence of depression. Furthermore, the geriatric population in the United States are growing, which would provide additional chances for market players in the region. During the COVID-19 epidemic in the United States, the prevalence of depression increased. According to a study published in JAMA Network Open 2020, the prevalence of depression symptoms in the United States was more than three times greater during COVID-19 than before the pandemic. This was primarily due to increasing stress levels as a result of job loss and social isolation. As a result of the aforementioned considerations, COVID-19 is predicted to boost the antidepressant market in the United States during the pandemic. Furthermore, the studied market is driven by an increase in FDA approvals and pipeline goods by significant companies focused on the region. The report also helps in understanding Global Antidepressant Market dynamics, structure by analyzing the market segments and project the Global Antidepressant Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antidepressant Market make the report investor’s guide.

Global Antidepressant Market Scope: Inquire before buying

Global Antidepressant Market 2

Global Antidepressant Market, By Region:

• North America • Europe • South America • MEA • APAC

Global Antidepressant Market, Key players:

• AstraZeneca plc • Eli Lilly and Company • Forest Laboratories • GlaxoSmithKline plc • H. Lundbeck A/S • Johnson & Johnson • Merck & Co., Inc. • Pfizer, Inc. • Sanofi S.A. • Allergan PLC • Sun Pharmaceuticals Pvt Ltd. • Alkermes Plc • Bristol Myers Squibb Co • Teva Pharmaceutical Industries Ltd. • Takeda Pharmaceutical Co. Ltd.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Antidepressant Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Antidepressant Market 3.4. Geographical Snapshot of the Antidepressant Market, By Manufacturer share 4. Global Antidepressant Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Antidepressant Market 5. Supply Side and Demand Side Indicators 6. Global Antidepressant Market Analysis and Forecast, 2019-2026 6.1. Global Antidepressant Market Size & Y-o-Y Growth Analysis. 7. Global Antidepressant Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 7.1.1. Selective Serotonin Reuptake Inhibitor (SSRI) 7.1.2. Serotonin-norepinephrine Reuptake Inhibitor (SNRI) 7.1.3. Tricyclic Antidepressant (TCA) 7.1.4. Monoamine Oxidase Inhibitor (MAOI) 7.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 7.2.1. Major Depressive Disorder 7.2.2. Obsessive-compulsive Disorder (OCD) 7.2.3. Generalized Anxiety Disorder (GAD) 7.2.4. Panic Disorder (PD) 8. Global Antidepressant Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Antidepressant Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 9.1.1. Selective Serotonin Reuptake Inhibitor (SSRI) 9.1.2. Serotonin-norepinephrine Reuptake Inhibitor (SNRI) 9.1.3. Tricyclic Antidepressant (TCA) 9.1.4. Monoamine Oxidase Inhibitor (MAOI) 9.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 9.2.1. Major Depressive Disorder 9.2.2. Obsessive-compulsive Disorder (OCD) 9.2.3. Generalized Anxiety Disorder (GAD) 9.2.4. Panic Disorder (PD) 10. North America Antidepressant Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Antidepressant Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 12. Canada Antidepressant Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 13. Mexico Antidepressant Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 14. Europe Antidepressant Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 15. Europe Antidepressant Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Antidepressant Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 17. France Antidepressant Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 18. Germany Antidepressant Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 19. Italy Antidepressant Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 20. Spain Antidepressant Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 21. Sweden Antidepressant Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 22. CIS Countries Antidepressant Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 23. Rest of Europe Antidepressant Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 24. Asia Pacific Antidepressant Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 25. Asia Pacific Antidepressant Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Antidepressant Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 27. India Antidepressant Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 28. Japan Antidepressant Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 29. South Korea Antidepressant Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 30. Australia Antidepressant Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 31. ASEAN Antidepressant Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 32. Rest of Asia Pacific Antidepressant Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 33. Middle East Africa Antidepressant Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 34. Middle East Africa Antidepressant Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Antidepressant Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 36. GCC Countries Antidepressant Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 37. Egypt Antidepressant Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 38. Nigeria Antidepressant Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 39. Rest of ME&A Antidepressant Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 40. South America Antidepressant Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 41. South America Antidepressant Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Antidepressant Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 43. Argentina Antidepressant Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 44. Rest of South America Antidepressant Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Depressive Disorder, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Antidepressant Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Pfizer Inc. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Torrent Pharmaceuticals Ltd. 45.3.3. Lupin Limited 45.3.4. Zydus Cadila Healthcare Ltd. 45.3.5. Cipla Limited 45.3.6. Genesis Remedies 45.3.7. Sanofi 45.3.8. Medley Pharmaceuticals Limited 45.3.9. Genesis Biotec Inc. 45.3.10. Biomax 45.3.11. ZCL Chemicals Ltd. 45.3.12. Olon S.p.A. 45.3.13. AASraw Biochemical Technology Co., Ltd. 45.3.14. Changzhou Pharmaceutical Factory (CPF) 45.3.15. Almelo Pvt. Ltd. 45.3.16. Angels Pharma India Pvt. Ltd. 45.3.17. ARITE Pharmaceutical Co., Ltd. 45.3.18. Bal Pharma Limited. 45.3.19. Bazayan and Co. 45.3.20. Aurobindo Pharma Ltd. 45.3.21. Hikal Ltd. 45.3.22. Glenmark Life Sciences 45.3.23. Dongbang FTL 46. Primary Key Insights

About This Report

Report ID109273
Category Healthcare
Published DateJune 2021
Updated Date
Contact Us